3 results
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
The following table presents the compensation awarded to or earned by or paid to all individuals who served as non-employee directors during the year ended December 31, 2023.
Name | Fees Earned or Paid in Cash ($)(1) | Option Awards ($)(2)(3)(4) | Total ($) | |||||||||||||||||
Bruce C. Cozadd | 69,030 | 321,455 | 390,485 | |||||||||||||||||
Dan Becker, M.D., Ph.D. | 29,637 | 321,455 | 351,092 | |||||||||||||||||
Henry O. Gosebruch(5) | 41,879 | 976,798 | 1,018,677 | |||||||||||||||||
Patrick Machado J.D. | 80,740 | 321,455 | 402,195 | |||||||||||||||||
Beth Seidenberg, M.D. | 28,054 | 321,455 | 349,509 | |||||||||||||||||
Dawn Svoronos | 55,215 | 321,455 | 376,670 | |||||||||||||||||
Lynn Tetrault(6) | 1,822 | 480,440 | 482,262 | |||||||||||||||||
Alan Colowick(7) | — | — | — |
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
(in thousands, except share data)
Redeemable Convertible Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Gain (Loss) | Total Stockholders’ Equity (Deficit) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Balance at January 1, 2021 | 4,056,795 | $ | 7,916 | 2,839,748 | $ | — | $ | 1 | $ | (467) | $ | — | (466) | Issuance of Series B redeemable convertible preferred stock for cash, net of issuance costs of $296 | 12,228,923 | 124,704 | — | — | — | — | — | Stock-based compensation expense | — | — | — | — | 233 | — | — | 233 | Issuance of common stock upon exercise of options | — | — | 20,284 | 16 | — | — | 16 | Net loss | — | — | — | — | — | (41,839) | — | (41,839) | Balance at December 31, 2021 | 16,285,718 | $ | 132,620 | $ | 2,860,032 | $ | — | $ | 250 | $ | (42,306) | $ | — | $ | (42,056) | Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $26 | 12,228,923 | 124,974 | — | — | — | — | — | — | Issuance of Series C redeemable convertible preferred stock, net of derivative liability of $10,778 and issuance costs of $223 | 12,228,881 | 138,999 | — | — | — | — | — | — | Issuance of restricted stock awards | — | — | 498,940 | — | — | — | — | — | Repurchase and retirement of unvested founders’ common stock | — | — | (591,613) | — | — | — | — | — | Stock-based compensation expense | — | — | — | — | 4,052 | — | — | 4,052 | Net loss | — | — | — | — | — | (64,772) | — | (64,772) | Unrealized loss on short-term marketable securities, net | — | — | — | — | — | — | (86) | (86) | Balance at December 31, 2022 | 40,743,522 | $ | 396,593 | 2,767,359 | $ | — | $ | 4,302 | $ | (107,078) | $ | (86) | $ | (102,862) | Issuance of common stock in connection with ValenzaBio acquisition (Note 3) | — | — | 18,885,731 | — | 128,735 | — | — | 128,735 | Issuance of common stock upon initial public offering, net of underwriting discounts commissions and issuance costs of $47,354 | — | — | 34,500,000 | — | 573,644 | — | — | 573,644 | Conversion of redeemable convertible preferred stock into common stock in connection with initial public offering | (40,743,522) | (396,593) | 40,743,522 | 1 | 396,592 | — | — | 396,593 | Issuance of common stock upon settlement of restricted stock units, net of shares withheld for taxes | — | — | 303,237 | — | (8,325) | — | — | (8,325) | Stock-based compensation expense | — | — | — | — | 47,318 | — | — | 47,318 | Issuance of common stock under the employee stock purchase plan | — | — | 24,164 | — | 149 | — | — | 149 | Issuance of common stock upon exercise of options | — | — | 641,877 | — | 2,478 | — | — | 2,478 | Net loss | — | — | — | — | — | (381,641) | — | (381,641) | Unrealized gain on short-term marketable securities, net | — | — | — | — | — | — | 248 | 248 | Balance at December 31, 2023 | — | $ | — | 97,865,890 | $ | 1 | $ | 1,144,893 | $ | (488,719) | $ | 162 | $ | 656,337 |
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
Year Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash flows from operating activities: | Net loss | $ | (381,641) | $ | (64,772) | $ | (41,839) | Adjustments to reconcile net loss to net cash used in operations: | Stock-based compensation expense | 47,318 | 4,052 | 233 | Expense related to acquired in-process research and development assets | 133,057 | — | 25,000 | Net amortization of premiums and accretion of discounts on short-term marketable securities | (10,495) | (246) | — | Change in fair value of derivative tranche liability | (10,291) | (487) | — | Depreciation and amortization expense | 115 | — | — | Non-cash lease expense | 153 | — | — | Changes in assets and liabilities: | Prepaid expense and other current assets | (11,313) | (941) | (49) | Prepaid expenses and other assets, non-current | 1,528 | (1,964) | — | Accounts payable | 34,443 | 3,776 | 1,119 | Accrued research and development expenses | 24,914 | (3,980) | 9,697 | Accrued compensation and other current liabilities | 1,691 | 3,042 | 860 | Operating lease liability | (154) | — | — | Severance liability | 970 | — | — | Net cash used in operating activities | (169,705) | (61,520) | (4,979) | Cash flows from investing activities | ValenzaBio assets acquisition cash acquired, net of acquisition costs | 10,007 | — | — | Cash paid to acquire in-process research and development assets | (10,000) | — | (25,000) | Purchase of marketable securities | (956,512) | (175,970) | — | Proceeds from maturities of short-term marketable securities | 373,359 | 128,179 | — | Sales of marketable securities | 137,696 | — | — | Purchase of property, plant and equipment | (2,294) | — | — | Payments for ValenzaBio Acquisition costs | — | (83) | — | Net cash used in investing activities | (447,744) | (47,874) | (25,000) | Cash flows from financing activities | Issuance of common stock upon initial public offering, net of commissions and issuance costs | 574,134 | — | — | Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | 2,627 | — | 16 | Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs | — | 263,973 | 124,704 | Proceeds allocated to the derivative tranche liability | 10,778 | — | Payments for deferred offering costs | — | (489) | — | Taxes paid related to net share settlement of restricted stock units | (8,325) | — | — | Net cash provided by financing activities | 568,436 | 274,262 | 124,720 | Net increase (decrease) in cash and cash equivalents | (49,013) | 164,868 | 94,741 | Cash and cash equivalents, at beginning of year | 267,110 | 102,242 | 7,501 | Cash and cash equivalents, at end of year | $ | 218,097 | $ | 267,110 | $ | 102,242 |
- Prev
- 1
- Next